..."Monoclonal antibodies directed against CCR5, i

..."Monoclonal antibodies directed against CCR5, including leronlimab (PRO-140), have been tested in clinical populations like HIV-1, oncology, and COVID-19 [232,233,234]. These studies confirm sustained receptor occupancy, predictable pharmacokinetics, and a favorable safety profile. Although no neuropathic pain-specific clinical data are currently available, the immunomodulatory actions of leronlimab align well with mechanistic pathways implicated in neuroinflammatory pain. The long-lasting therapeutic effect and receptor interaction of monoclonal antibodies could be helpful in chronic pain diseases requiring suppression of immune-neuronal signaling"...